Clinical significance of elevated serum levels of matrix metalloproteinase-3 and C-reactive protein in patients with rheumatoid arthritis

Hayato Nagasawa, Hideto Kameda, Koichi Amano, Tsutomu Takeuchi

研究成果: Article

2 引用 (Scopus)

抄録

Aim: Serum levels of C-reactive protein (CRP) and matrix metalloproteinase-3 (MMP-3) are used as indicators of the activity of rheumatoid arthritis (RA). The aim of this study was to characterize the clinical features of patients showing exclusive elevation of either serum CRP or MMP-3, and the differences in the time-course of changes between the serum levels of MMP-3 and CRP after initiation of therapy. Methods: A total of 129 RA patients were classified into four groups according to the serum levels of CRP and MMP-3 at the time of enrolment: Negative for both CRP and MMP-3 levels; positive for both; positive for CRP alone (CRP-positive group); and positive for MMP-3 alone (MMP-3-positive group). The analysis included evaluation of the serum CRP and MMP-3 levels, and the Lansbury Articular Index at enrolment and at final observation. Results: In the CRP-positive group (19%), 21% of the patients remained CRP-positive at the final observation; 42% became double-negative, and 31% became double-positive. In contrast, in the MMP-3-positive group (9%), about two-thirds of the patients remained MMP-3-positive at the final observation. The disease duration in the MMP-3-positive group was significantly longer, and the ratio of the number of large swollen joints to the total number of swollen joints was higher as compared with that in the other groups. Furthermore, elevated serum CRP responded faster to disease-modifying antirheumatic drug therapy than elevated serum MMP-3. Conclusions: Serum CRP is a better predictor of the response to treatment than serum MMP-3, which is associated to a greater extent with large joint involvement.

元の言語English
ページ(範囲)295-299
ページ数5
ジャーナルAPLAR Journal of Rheumatology
10
発行部数4
DOI
出版物ステータスPublished - 2007 12
外部発表Yes

Fingerprint

Matrix Metalloproteinase 3
C-Reactive Protein
Rheumatoid Arthritis
Serum
Blood Proteins
Joints
Observation
Antirheumatic Agents
Protein C

ASJC Scopus subject areas

  • Rheumatology

これを引用

@article{16e961260d8144968690583ffc221a9b,
title = "Clinical significance of elevated serum levels of matrix metalloproteinase-3 and C-reactive protein in patients with rheumatoid arthritis",
abstract = "Aim: Serum levels of C-reactive protein (CRP) and matrix metalloproteinase-3 (MMP-3) are used as indicators of the activity of rheumatoid arthritis (RA). The aim of this study was to characterize the clinical features of patients showing exclusive elevation of either serum CRP or MMP-3, and the differences in the time-course of changes between the serum levels of MMP-3 and CRP after initiation of therapy. Methods: A total of 129 RA patients were classified into four groups according to the serum levels of CRP and MMP-3 at the time of enrolment: Negative for both CRP and MMP-3 levels; positive for both; positive for CRP alone (CRP-positive group); and positive for MMP-3 alone (MMP-3-positive group). The analysis included evaluation of the serum CRP and MMP-3 levels, and the Lansbury Articular Index at enrolment and at final observation. Results: In the CRP-positive group (19{\%}), 21{\%} of the patients remained CRP-positive at the final observation; 42{\%} became double-negative, and 31{\%} became double-positive. In contrast, in the MMP-3-positive group (9{\%}), about two-thirds of the patients remained MMP-3-positive at the final observation. The disease duration in the MMP-3-positive group was significantly longer, and the ratio of the number of large swollen joints to the total number of swollen joints was higher as compared with that in the other groups. Furthermore, elevated serum CRP responded faster to disease-modifying antirheumatic drug therapy than elevated serum MMP-3. Conclusions: Serum CRP is a better predictor of the response to treatment than serum MMP-3, which is associated to a greater extent with large joint involvement.",
keywords = "CRP, Lansbury Articular Index, Swollen joint count",
author = "Hayato Nagasawa and Hideto Kameda and Koichi Amano and Tsutomu Takeuchi",
year = "2007",
month = "12",
doi = "10.1111/j.1479-8077.2007.00309.x",
language = "English",
volume = "10",
pages = "295--299",
journal = "International Journal of Rheumatic Diseases",
issn = "1756-1841",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Clinical significance of elevated serum levels of matrix metalloproteinase-3 and C-reactive protein in patients with rheumatoid arthritis

AU - Nagasawa, Hayato

AU - Kameda, Hideto

AU - Amano, Koichi

AU - Takeuchi, Tsutomu

PY - 2007/12

Y1 - 2007/12

N2 - Aim: Serum levels of C-reactive protein (CRP) and matrix metalloproteinase-3 (MMP-3) are used as indicators of the activity of rheumatoid arthritis (RA). The aim of this study was to characterize the clinical features of patients showing exclusive elevation of either serum CRP or MMP-3, and the differences in the time-course of changes between the serum levels of MMP-3 and CRP after initiation of therapy. Methods: A total of 129 RA patients were classified into four groups according to the serum levels of CRP and MMP-3 at the time of enrolment: Negative for both CRP and MMP-3 levels; positive for both; positive for CRP alone (CRP-positive group); and positive for MMP-3 alone (MMP-3-positive group). The analysis included evaluation of the serum CRP and MMP-3 levels, and the Lansbury Articular Index at enrolment and at final observation. Results: In the CRP-positive group (19%), 21% of the patients remained CRP-positive at the final observation; 42% became double-negative, and 31% became double-positive. In contrast, in the MMP-3-positive group (9%), about two-thirds of the patients remained MMP-3-positive at the final observation. The disease duration in the MMP-3-positive group was significantly longer, and the ratio of the number of large swollen joints to the total number of swollen joints was higher as compared with that in the other groups. Furthermore, elevated serum CRP responded faster to disease-modifying antirheumatic drug therapy than elevated serum MMP-3. Conclusions: Serum CRP is a better predictor of the response to treatment than serum MMP-3, which is associated to a greater extent with large joint involvement.

AB - Aim: Serum levels of C-reactive protein (CRP) and matrix metalloproteinase-3 (MMP-3) are used as indicators of the activity of rheumatoid arthritis (RA). The aim of this study was to characterize the clinical features of patients showing exclusive elevation of either serum CRP or MMP-3, and the differences in the time-course of changes between the serum levels of MMP-3 and CRP after initiation of therapy. Methods: A total of 129 RA patients were classified into four groups according to the serum levels of CRP and MMP-3 at the time of enrolment: Negative for both CRP and MMP-3 levels; positive for both; positive for CRP alone (CRP-positive group); and positive for MMP-3 alone (MMP-3-positive group). The analysis included evaluation of the serum CRP and MMP-3 levels, and the Lansbury Articular Index at enrolment and at final observation. Results: In the CRP-positive group (19%), 21% of the patients remained CRP-positive at the final observation; 42% became double-negative, and 31% became double-positive. In contrast, in the MMP-3-positive group (9%), about two-thirds of the patients remained MMP-3-positive at the final observation. The disease duration in the MMP-3-positive group was significantly longer, and the ratio of the number of large swollen joints to the total number of swollen joints was higher as compared with that in the other groups. Furthermore, elevated serum CRP responded faster to disease-modifying antirheumatic drug therapy than elevated serum MMP-3. Conclusions: Serum CRP is a better predictor of the response to treatment than serum MMP-3, which is associated to a greater extent with large joint involvement.

KW - CRP

KW - Lansbury Articular Index

KW - Swollen joint count

UR - http://www.scopus.com/inward/record.url?scp=36749051813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749051813&partnerID=8YFLogxK

U2 - 10.1111/j.1479-8077.2007.00309.x

DO - 10.1111/j.1479-8077.2007.00309.x

M3 - Article

AN - SCOPUS:36749051813

VL - 10

SP - 295

EP - 299

JO - International Journal of Rheumatic Diseases

JF - International Journal of Rheumatic Diseases

SN - 1756-1841

IS - 4

ER -